Curis INC

Curis, Inc. has received notification from Nasdaq that it has regained compliance with the Bid Price Rule and will be subject to a one-year monitoring period.

Curis, Inc. has filed a certificate of amendment to its Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its common stock, effective July 2, 2026.

Curis, Inc. has filed an amendment to its Form 8-K to announce the expected market effective date for its previously announced reverse stock split.

Curis, Inc. announced its stockholders approved amendments to its Restated Certificate of Incorporation to effect a reverse stock split, with the Board subsequently approving a 1-for-20 ratio.

Curis, Inc. shareholders have voted to approve a reverse stock split at a ratio between 1-for-5 and 1-for-25.

Curis, Inc. announced its first-quarter 2026 business update and financial results, highlighting progress in emavusertib clinical trials for lymphoma and leukemia, alongside a net loss of $24.2 million.

Curis, Inc. files its Q1 2026 10-Q, detailing ongoing development of emavusertib, significant net loss, and substantial doubt about its ability to continue as a going concern.

Curis, Inc. reported a net loss of $26.9 million for the nine months ended September 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern, leading to the sale of its Erivedge royalty interest post-period end.

Curis, Inc. reports continued losses and significant doubt about its ability to continue as a going concern, despite progress in its emavusertib clinical programs.

Curis Inc. reports a net loss for Q1 2025 and acknowledges substantial doubt about its ability to continue as a going concern.

Curis Inc. reported its third quarter 2024 financial results, highlighting ongoing research and development efforts for emavusertib while also acknowledging substantial doubt about the company's ability to continue as a going concern.

Curis Inc. reported its financial results for the second quarter of 2024, highlighting ongoing clinical trials for emavusertib and a strategic shift to focus on key programs.

Curis, Inc. reported a net loss of $7.6 million for 2025 and raised substantial doubt about its ability to continue as a going concern, despite recent financing and ongoing clinical trials for its lead drug candidate, emavusertib.

Curis Inc. details its financial results for 2024 and provides updates on the clinical development of its lead drug candidate, emavusertib, including discussions with regulatory agencies regarding potential accelerated approval pathways.

Curis Inc.'s annual 10-K filing provides a comprehensive overview of its securities, financial performance, regulatory environment, and strategic direction, highlighting the development of emavusertib and its financial challenges.

Curis Inc. Director Marc Rubin was granted 6,800 stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. Director Kenneth I. Kaitin has been granted 6,800 non-qualified stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. director John Hohneker has been granted a non-qualified stock option for 6,800 shares with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. Director Martyn D. Greenacre was granted stock options for 6,800 shares of common stock.

Curis Inc. Director Anne Elizabeth Borgman acquired 6,800 stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Diantha Duvall, CFO of Curis Inc., was granted 48,285 employee stock options with an exercise price of $5.29.

Curis, Inc. has scheduled a special meeting for June 25, 2026, to seek shareholder approval for a reverse stock split ranging from 1-for-5 to 1-for-25.

Curis, Inc. has scheduled its 2026 annual meeting for May 19, 2026, to vote on director elections, executive compensation, and a significant increase in authorized common stock.

Curis, Inc. calls a special meeting to vote on significantly increasing authorized shares, approving a recent PIPE financing's conversion, and establishing a new incentive plan.

Curis, Inc. has filed its definitive proxy statement with the SEC concerning its upcoming 2025 annual meeting.

Curis, Inc. is holding its annual stockholder meeting on May 20, 2025, to vote on key proposals including director elections, executive compensation, auditor ratification, stock incentive plan amendments, increasing authorized shares, and approving warrant issuance.

Curis, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Curis, Inc. filed an S-1 registration statement for the resale of up to 4,615,382 shares of common stock underlying recently issued warrants, while also disclosing substantial doubt about its ability to continue as a going concern.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing a beneficial ownership of 4.99% of Curis, Inc.'s common stock as of March 31, 2026.

Thomas A. Satterfield, Jr. has filed a Schedule 13G, reporting beneficial ownership of 9.9% of Curis, Inc.'s common stock as of March 31, 2026.

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in Curis, Inc. common stock.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.99% of Curis, Inc. common stock as of March 31, 2026.

Nantahala Capital Partners Limited Partnership has reported beneficial ownership of 2,944,000 shares of Curis, Inc. common stock, representing 6.98% of the outstanding shares.

Stonepine Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Curis Inc., totaling 4,025,992 common shares.